Q4 highlights that Biovica has secured two contracts with Contigo Health and MedIncrease, access to ...
Endomines agreed on convertible loan financing with Finnish investors to start production at Hosko a...
SEK 266m directed share issue: ~15% disc., ~14% dilution New institutional backing helps mitigate fu...
Anette Billing resigns as CEOChairman, Sverre Bjerkeli takes over as interim CEOSearch for a new CEO...
We expect high inventories at retailers to have continued burdening Fiskars' sales in Q2.
Eevia Health Plc (publ) (”Eevia Health”, “Eevia” or “the Company”) is at a stage where the Company i...
STENOCARE published on June 20 its Q1-report for 2023.
CirChems intäkter uppgick till 564 KSEK under Q1-23, att jämföra med 366 KSEK under föregående kvart...
Sommarens höjdpunkt i biotech-Sverige Sommarens stora händelse på den svenska biotechscenen är resul...
Double Bond Pharma är framme i ett intressant läge där dess läkemedelskandidat SI-053 för behandling...
Q2 report due 18 July Q2'23e sales of SEK 464m, EBITA of SEK 60m Share trading at 6x-5x '23e-'25e EV...
Q2 report due 19 July Q2'23e sales of SEK 195m, adj.
Nytt motiverat värde och uppdaterade prognoser Vi har uppdaterat våra prognoser och vårt motiverade ...
Stark avslutning på 2022/23 ScandiDos redovisar fortsatt momentum i Asien under Q4, vilket bidrog ti...
Redeye comments on the recent progress update from Scibase and our research into fee schedules for s...
There was plenty of IgAN attention including new and emerging treatment modalities.
The past three years have not been easy for Estonia's biggest port utility, Tallinna Sadam, but reco...
Redeye was a little surprised to hear that Jonas Nilsson has been appointed new CEO of Impact Coatin...
Analysguiden initierar bevakning på forskningsbolaget Emplicure och inleder med ett motiverat värde ...
Redeye comments on Energy Save’s Q4’22/23 report, which showed lower sales and profitability than ex...
